Pfizer Reports Strong Revenue and EPS Beat Driven by Primary Care Growth
Pfizer has reported financial results that exceeded analyst expectations, posting a non-GAAP EPS of $0.87—beating estimates by $0.14—and total revenue of $16.58 billion, which surpassed projections by $700 million. The company's performance was bolstered by a sharp rebound in its Primary Care segment and continued momentum within its Oncology portfolio. To optimize its commercial structure, Pfizer transitioned several off-patent branded products, generic sterile injectables, and biosimilars from the Specialty Care and Oncology divisions into a newly established Hospital and Biosimilars portfolio. Looking forward, market attention is shifting toward Pfizer's obesity pipeline as analysts evaluate diverging growth expectations for upcoming quarters.
Tickers: $PFE
Topics: corporate restructuring earnings beat financial results revenue growth
Read the full article at Seeking Alpha
Part of the story UroGen Pharma Reports Strong Revenue Growth Driven by Zosturi Sales (7 articles)